



Clinical Trials & Research

The Retina Partners are committed to advancing treatment for a variety of retinal conditions. Our physicians take pride in being involved in teaching and research as it relates to the betterment of vision. As such, The Retina Partners are involved in multiple clinical trials to help with retinal conditions in the future.

If you are interested in learning more about available clinical trials, please contact us through this website or at [\(877\) 3-RETINA](tel:877-3-RETINA).

We are involved in the following trials:

DERBY

A Phase III, multi-center, randomized, double-masked, sham-controlled study to compare the efficacy and safety of intravitreal APL-2 therapy with sham injections in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

OPTHEA (currently enrolling)

A dose-ranging study of intravitreal OPT-302 in combination with ranibizumab, compared with ranibizumab alone, in participants with neovascular age-related macular degeneration (wet AMD).

ACACIA (Coming soon)

A Phase III study to assess the safety and efficacy of abicipar pegol compared with ranibizumab in patients with diabetic macular edema (DME) with center involvement.

CEDAR (closed)

A Phase III study to assess the safety and efficacy of abicipar compared with ranibizumab in treatment-naive patients with neovascular age-related macular degeneration.

LADDER (closed)

A Phase II study to investigate the efficacy and safety of the ranibizumab port delivery system for sustained delivery of ranibizumab in patients with subfoveal neovascular age-related macular degeneration.

PANORAMA (closed)

A Phase III, double-masked, randomized study of the efficacy and safety of intravitreal aflibercept injection in patients with moderately severe to severe nonproliferative diabetic retinopathy.

AVENUE (Closed)

A Phase II study to investigate the safety, tolerability, pharmacokinetics, and efficacy of RO6867461 administered intravitreally in patients with neovascular age-related macular degeneration.

GX 29455 (Closed)

A Phase II sham injection-controlled exposure-response study of lampalizumab intravitreal injections administered every two weeks or every four weeks for geographic atrophy.

OLEi GX28198 (Closed)

A Phase III multicenter, open-label extension study to evaluate the long-term safety and tolerability of lampalizumab (FCFD4514S) in patients with geographic atrophy who have completed Genentech-sponsored lampalizumab studies.

ONYX (Closed)

A randomized, double-masked, active-controlled phase 2 study of the efficacy, safety, and tolerability of repeated doses of intravitreal REGN910-3 in patients with neovascular age-related macular degeneration.